Study #2023-1051
A phase 1, multicenter, open-label study of REM-422, an MYB mRNA degrader, in patients with relapsed/refractory AML or higher-risk MDS
MD Anderson Study Status
Enrolling
Treatment Agent
REM-422
Description
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory
Study phase:
Phase I
Physician name:
Courtney DiNardo
Department:
Leukemia
For general questions about clinical trials:
1-866-419-2881
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.